Anti-CD20 monoclonal antibody therapy and minimal residual disease status of T-cell/histiocyte-rich large B cell non-hodgkin lymphoma. [Carta ao Editor]

Anti-CD20 monoclonal antibody therapy and minimal residual disease status of T-cell/histiocyte-rich large B cell non-hodgkin lymphoma. [Carta ao Editor] (2011)

A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas

ABNT

VALERA, Elvis Terci; QUEIROZ, Rosane Gomes de Paula; BRASSESCO, María Sol; et al. Anti-CD20 monoclonal antibody therapy and minimal residual disease status of T-cell/histiocyte-rich large B cell non-hodgkin lymphoma. [Carta ao Editor]. Pediatric Blood & Cancer[S.l: s.n.], 2011.
APA

Valera, E. T., Queiroz, R. G. de P., Brassesco, M. S., Scrideli, C. A., Neves, F., & Tone, L. G. (2011). Anti-CD20 monoclonal antibody therapy and minimal residual disease status of T-cell/histiocyte-rich large B cell non-hodgkin lymphoma. [Carta ao Editor]. Pediatric Blood & Cancer. Hoboken.
NLM

Valera ET, Queiroz RG de P, Brassesco MS, Scrideli CA, Neves F, Tone LG. Anti-CD20 monoclonal antibody therapy and minimal residual disease status of T-cell/histiocyte-rich large B cell non-hodgkin lymphoma. [Carta ao Editor]. Pediatric Blood & Cancer. 2011 ;
Vancouver

Valera ET, Queiroz RG de P, Brassesco MS, Scrideli CA, Neves F, Tone LG. Anti-CD20 monoclonal antibody therapy and minimal residual disease status of T-cell/histiocyte-rich large B cell non-hodgkin lymphoma. [Carta ao Editor]. Pediatric Blood & Cancer. 2011 ;